Skip to main content

Table 3 The clinical characteristics according to episode of cluster bout treated GT (N = 14)

From: Preventive therapy with galcanezumab for two consecutive cluster bouts in patients with episodic cluster headache: an observational multicenter study

 

1st GT treated episode

95% CI

P

2nd GT treated episode

95% CI

P

1 week before GT

3 weeks after GT

1 week before GT

3 weeks after GT

Headache characters

 Headache days

7.0 (5.0,7.0)

0 (0, 2.5)

[3.4, 6.2]

 < 0.001*

4.0 (4.0, 7.0)

2.0 (0.0, 7.0)

[0.1, 4.2]

0.041*

 Daily headache frequency

1.0 (1.0,1.6)

0 (0,0.6)

[0.6, 1.5]

 < 0.001*

1.0 (0.9, 2.2)

0.4 (0.0, 1.0)

[0.2, 1.9]

0.021*

 Number of total headaches

7.0 (7.0,11.8)

0 (0,4.0)

[4.3, 10.4]

 < 0.001*

7.0 (6.5, 15.5)

2.0 (0.0, 7.8)

[1.4, 13.4]

0.019*

 Headache intensity (VAS)

8.0 (7.0,9.0)

0.0 (0.0,3.3)

[3.8, 8.2]

 < 0.001*

8.0 (7.8,9.0)

3.0 (0.0,5.0)

[3.6, 6.5]

 < 0.001*

3 weeks after—1 week before

P

 Headache days

– 5.0 (–7.0, –2.8)

–3.0 (–4.0, 0.5)

[-4.3, -1.0]

0.004*

 Daily headache frequency

– 1.0 (–1.4, –0.6)

–0.9 (–1.8,0.0)

[-3.0, 4.3]

0.965

 Number of total headaches

– 7.0 (–10.3, –4.5)

–6.0 (–12.5, –1.5)

[-6.0, 3.6]

0.975

 Headache intensity (VAS)

– 7.5 (–9.0, –2.3)

– 5.0 (–7.3, –2.8)

[-3.5, 1.0]

0.251

PGI-I, n (%) a

 Very much better

 

8 (57.1)

3 (21.4)

 

0.300

 Much better

 

4 (28.6)

6 (42.9)

 

 A little better

 

1 (7.1)

3 (21.4)

 

 No change

 

1 (7.1)

2 (14.3)

 

ADR, n (%)

4 (28.6)

3 (21.4)

 

0.671

 Skin rash

0 (0.0)

 

2(14.3)

 

0.481

 Constipation

4 (28.5)

 

1 (7.1)

 

0.326

  1. Data presented as median (25th to 75th quartile) or number (%). These p-values are based on paired t-test or chi-square test
  2. GT Galcanezumab therapy, CI Confidence Interval, VAS Visual Analog Scale, PGI-I Patient Global Impression of improvement, Clinical Global Impression, ADR Adverse Drug Reaction
  3. * p-value<0.05, a Fisher's Exact Test